Skip to main content

Table 4 Molecular targeted therapies with demonstrated preclinical activity as radiosensitizers

From: Radiosensitizers in cervical cancer. Cisplatin and beyond

Epidermal Growth Factor Receptor inhibitors
Cetuximab
Gefitinib
Trastuzumab
CI-1033 (pan-ErbB tyrosine kinase inhibitor)
Farnesyl Transferase Inhibitors
FTI-277
L744832
BIM-46068
Ras-Mediated Downstream Pathways inhibitors
AS-ON Raf
PI3K inhibitor: LY294002
PI3K inhibitor: wortamannin
AS-ON p21
MEK inhibitor
Agents that target apoptosis, cell cycle, NF-Kappa-B
Flavopiridol
PS-341
UCN-01
COX-2 Inhibitors
SC-236
NC-398
Rofecoxib
Antiangiogenic Agents
mAb-VEGF
SU5416
SU5416
SU6668
mAb-VEGF-2
Angiostatin
Endostatin
Histone deacetylase inhibitors
Valproic acid
MS275
SAHA